£52.00

It has never been this cheap. We have no record of a lower price.

£52 today · cheaper than every other day in the last 3 months

Oberflächliche Tumore der Blase: Immunohistochemische prognostische Biomarker

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 55 days · 55 data points (no recent data)

Historical
Generating forecast…
£52.00 £49.40 £50.44 £51.48 £52.52 £53.56 £54.60 23 July 2026 05 August 2026 19 August 2026 01 September 2026 15 September 2026
View at Amazon ↗

Price data last checked 36 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 55 days • 1 price levels

Days at Price
55 days 0 14 28 41 55 £52 Days at Price

Price Analysis

Most common price: £52 (55 days, 100.0%)

Price range: £52 - £52

Price levels: 1 different prices over 55 days

Description

Nicht muskelinfiltrierende Blasentumore oder TVNIM sind Tumore mit unvorhersehbarem Verlauf. Es wurden endoskopische und histologische Prognosefaktoren ermittelt, die aber dennoch unzureichend sind, was dazu führte, dass neue molekulare Prognosefaktoren vorgeschlagen wurden. Über einen Zeitraum von 6 Jahren (2008-2013) wurden 40 TVNIM gesammelt, an denen wir E-Cadherin, ein interzelluläres Adhäsionsmolekül, und β-Cathenin, ein mit E-Cadherin assoziiertes Molekül, immunhistochemisch untersuchten. Es wurde eine inverse Korrelation zwischen E-Cadherin einerseits und dem Stadium (p=0,001), dem Grad (p=0,0000000), dem Rezidiv (p=0,0000000), der Progression (p=0,01), dem SSR (p=0,00000001) und dem PFS (p=0,01) andererseits festgestellt. Es bestand auch eine Korrelation zwischen Beta-Cathenin einerseits und dem Stadium (p=0,05), dem Grad (p=0,02) und dem Rezidiv (p=0,02) andererseits.Die Negativität dieser beiden Antikörper würde eine "Erkennung" von Hochrisiko-IMTV ermöglichen, die von einer engeren Überwachung und/oder einer aggressiveren Behandlung profitieren könnten.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
22 February 2024
Listed Since
23 February 2024

Barcode

No barcode data available

Similar Products You Might Like

Management of Muscle Invasive Bladder Cancer (Management of Urology)
71% match

Management of Muscle Invasive Bladder Cancer (Management of Urology)

Springer

£74.21 12 Aug 2026
Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment: Proceedings of the Fifth International Workshop on Breast Cancer ... in Experimental Medicine and Biology)
70% match

Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment: Proceedings of the Fifth International Workshop on Breast Cancer ... in Experimental Medicine and Biology)

Springer

£79.08 04 Aug 2026
Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider
70% match

Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider

Springer

£89.78 21 Oct 2026
Management of Muscle Invasive Bladder Cancer, An Issue of Urologic Clinics of North America (Volume 53-4) (The Clinics: Surgery, Volume 53-4)
70% match

Management of Muscle Invasive Bladder Cancer, An Issue of Urologic Clinics of North America (Volume 53-4) (The Clinics: Surgery, Volume 53-4)

Elsevier

£85.99 05 Aug 2026
Bladder Cancer: A Practical Guide
70% match

Bladder Cancer: A Practical Guide

Springer

£154.53 14 Aug 2026
Bladder Cancer: Diagnosis, Therapeutics, and Management (Current Clinical Urology)
70% match

Bladder Cancer: Diagnosis, Therapeutics, and Management (Current Clinical Urology)

Humana

£80.65 04 Aug 2026
Carcinoma of the Bladder: Innovations in Management (Medical Radiology)
69% match

Carcinoma of the Bladder: Innovations in Management (Medical Radiology)

Springer

£77.49 08 Aug 2026
Urothelial Carcinoma: Methods and Protocols: 1655 (Methods in Molecular Biology, 1655)
69% match

Urothelial Carcinoma: Methods and Protocols: 1655 (Methods in Molecular Biology, 1655)

Humana

£80.67 07 Aug 2026
New Developments in Visual Attention Research (Psychology Research Progress)
69% match

New Developments in Visual Attention Research (Psychology Research Progress)

£119.99 15 Sep 2026
Advanced and Metastatic Renal Cell Carcinoma, An Issue of Urologic Clinics (Volume 47-3) (The Clinics: Surgery, Volume 47-3)
68% match

Advanced and Metastatic Renal Cell Carcinoma, An Issue of Urologic Clinics (Volume 47-3) (The Clinics: Surgery, Volume 47-3)

Elsevier

£69.11 13 Sep 2026
Upper Tract Urothelial Carcinoma
68% match

Upper Tract Urothelial Carcinoma

Springer

£88.21 08 Aug 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
68% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£108.01 10 Aug 2026
Imaging in Oncological Urology
68% match

Imaging in Oncological Urology

Springer

£81.74 08 Aug 2026
Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)
68% match

Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)

Humana

£108.01 06 Aug 2026
Advancing Gene Fusion Detection Towards Personalized Cancer Nanodiagnostics (Springer Theses)
68% match

Advancing Gene Fusion Detection Towards Personalized Cancer Nanodiagnostics (Springer Theses)

Springer

£72.93 07 Aug 2026
New Advances on Disease Biomarkers and Molecular Targets in Biomedicine
68% match

New Advances on Disease Biomarkers and Molecular Targets in Biomedicine

Humana

£88.21 19 Aug 2026
Brain Tumor Immunotherapy
68% match

Brain Tumor Immunotherapy

Humana

£129.64 08 Aug 2026
Cancer Immunology: 30 (Immunology and Medicine, 30)
68% match

Cancer Immunology: 30 (Immunology and Medicine, 30)

Springer

£113.76 08 Aug 2026
Cell Adhesion and Cytoskeletal Molecules in Metastasis: 9 (Cancer Metastasis - Biology and Treatment, 9)
68% match

Cell Adhesion and Cytoskeletal Molecules in Metastasis: 9 (Cancer Metastasis - Biology and Treatment, 9)

Springer

£99.91 08 Aug 2026
Prognostic variables in node-negative and node-positive breast cancer
68% match

Prognostic variables in node-negative and node-positive breast cancer

Springer

£153.04 05 Aug 2026
Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)
68% match

Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)

Humana

£37.01 10 Aug 2026
Genitourinary Cancer 1: 6 (Cancer Treatment and Research, 6)
68% match

Genitourinary Cancer 1: 6 (Cancer Treatment and Research, 6)

Springer

£86.27 08 Aug 2026
68% match

Molecular Insights for Harnessing Urine Biomarkers in Precision Medicine

Elsevier

£137.99 05 Aug 2026
Urologic Oncology: 19 (Cancer Treatment and Research, 19)
67% match

Urologic Oncology: 19 (Cancer Treatment and Research, 19)

Springer

£166.25 07 Aug 2026